FDA’s OPaSS promotion
This article was originally published in The Tan Sheet
Executive Summary
Deputy Director of the Office of Pharmacoepidemiology & Statistical Science (OPaSS) will be Jonca Bull, MD, FDA states May 2; the announcement is effective immediately. OPaSS Director Paul Seligman, MD, said Bull "will be responsible for the development and implementation of many of the drug safety and statistical strategic initiatives in OPaSS, in addition to assisting me with the management of the office." She most recently served as director of Office of Drug Evaluation V, which is being eliminated as part of CDER's reorganization (1"The Tan Sheet" Oct. 25, 2004, p. 3)...
You may also be interested in...
OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.